saxagliptin / Generic mfg. - LARVOL DELTA

Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus. (PubMed, Pharmacoepidemiol Drug Saf) - "DPP-4 inhibitors remain effective and well-tolerated options for managing T2DM."

Journal • Review • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Dipeptidyl peptidase-4 inhibitors and diabetic retinopathy in type 2 diabetes: A network meta-analysis of randomized clinical trials. (PubMed, J Diabetes Complications) - "Current randomized evidence indicates class-level neutrality of DPP-4 inhibitors on DR incidence, with no dose-response signal. Choice among gliptins may therefore be guided primarily by glycemic efficacy, safety, and participant characteristics rather than retinal risk."

Clinical • Journal • Retrospective data • Review • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Retinal Disorders • Type 2 Diabetes Mellitus

Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review. (PubMed, J Pers Med) - " We systematically searched PubMed, Scopus, and Web of Science for studies published from the earliest available records to 18 August 2025 using the following Boolean search terms: "miRNA AND gliclazide", "miRNA AND glibenclamide", "miRNA AND gliquidone", "miRNA AND glimepiride", "mirRNA AND metformin", "miRNA AND pioglitazone", "miRNA AND rosiglitazone", "miRNA AND sitagliptin", "miRNA AND vildagliptin", "miRNA AND alogliptin", "miRNA and saxagliptin", "miRNA AND linagliptin", "miRNA AND liraglutide", "miRNA and dulaglutide", "miRNA AND semaglutide", "miRNA AND tirzepatide", "miRNA AND lixisenatide", "miRNA AND empagliflozin", "miRNA AND dapagliflozin", miRNA AND insulin glargine", "miRNA AND insulin detemir", "miRNA AND insulin degludec", "miRNA AND..."

Journal • Review • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

ON TARGET DM: Comparison of Type 2 Diabetes Pharmacotherapy Regimens (clinicaltrials.gov) - P=N/A | N=241981 | Completed | Sponsor: Kaiser Permanente | Recruiting ➔ Completed | Trial completion date: Aug 2025 ➔ Mar 2025

Trial completion • Trial completion date • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Noninsulin drugs for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Case Report: NEUROD1 c.-108G>C mutation in a ketosis-prone MODY6 patient: implications for genetic testing and DPP-4 inhibitor therapy. (PubMed, Front Endocrinol (Lausanne)) - "Following individualized therapy with saxagliptin and acarbose, the patient achieved stable blood glucose control without insulin after 6 months, with partial recovery of islet function. This case supports that NEUROD1 mutations may retain incretin responsiveness, expanding therapeutic options for MODY6."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • Xerostomia • NEUROD1

Cardiovascular Sequel in Type-2 Diabetes Mellitus Patients on Various Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systemic Review and Meta-Analysis. (PubMed, Cureus) - "The systematic review and meta-analysis was conducted by utilizing widespread empirical research and randomized control trials (RCTs), evaluating sitagliptin, saxagliptin, alogliptin, and linagliptin. Sitagliptin and linagliptin appear neutral regarding HF risk. These findings highlight the importance of drug-specific evaluation when selecting a DPP-4 inhibitor for type-2 diabetic patients, particularly those having an elevated risk of heart failure."

Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Systemic Autoimmune Rheumatic Diseases in Patients with Type 2 Diabetes: A Population-Based Target Trial Emulation (ACR Convergence 2025) - "This study aimed to evaluate the effect of treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i) on the risk of new-onset SARD. This emulated target trial used electronic health records of adults with T2D who initiated either an SGLT2i (canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin) or a DPP4i (alogliptin, saxagliptin, linagliptin, or sitagliptin) between 2016 and 2024 from 101 U.S. healthcare organizations. Treatment with SGLT2i, especially dapagliflozin and empagliflozin, was associated with reduced risks of developing various SARD compared to DPP4i. These findings provide evidence for the broader immunomodulatory effects of SGLT2i. Prospective studies on the roles of SGLT2i in attenuating inflammation and autoimmunity are warranted to validate the finding."

Clinical • Ankylosing Spondylitis • Diabetes • Giant Cell Arteritis • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Metabolic Disorders • Musculoskeletal Pain • Rare Diseases • Rheumatoid Arthritis • Rheumatology • Scleroderma • Seronegative Spondyloarthropathies • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis • Type 2 Diabetes Mellitus • Vasculitis

Dietary Modulation of CYP3A4 and Its Impact on Statins and Antidiabetic Drugs: A Narrative Review. (PubMed, Pharmaceuticals (Basel)) - "Specific examples include simvastatin, atorvastatin, repaglinide, and saxagliptin, whose systemic exposure can be significantly altered by dietary factors. Clinicians should remain aware of potential CYP3A4-related food-drug interactions and consider dietary habits and supplement use in therapeutic decision-making. Future research should aim to integrate pharmacogenomics, gut microbiome profiling, and personalized nutrition in order to improve the prediction and prevention of clinically significant interactions."

Journal • Review • CYP3A4

Robson Ten-Group Classification Study of Cesarean Section Rates in Assiut Hospitals (clinicaltrials.gov) - P=N/A | N=770 | Not yet recruiting | Sponsor: Assiut University

New trial

Treatment with DPP4-inhibitors does not increase circulating autoantibodies for autoimmune bullous diseases in patients with type 2 diabetes (EADV 2025) - "Our findings align with previous studies showing no significant increase in AIBD-related autoantibodies in DPP4i- treated T2DM patients without a prior AIBD diagnosis. Limitations include older age among DPP4i users and limited DPP4i types (only sitagliptin and saxagliptin were prescribed). These results support the view that serologic testing should be reserved for patients with clinical suspicion of AIBD."

Clinical • Bullous Pemphigoid • Dermatology • Dermatopathology • Diabetes • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluation and comparison of efficacy and safety of mitochondrial modulator (Imeglimin) and DPP-4 inhibitors in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis. (PubMed, J Endocrinol Invest) - "Imeg and DPP-4i demonstrated favorable antidiabetic effects and good safety. Imeg exhibited comparable glycemic control to that of DPP-4i. Overall, Alog was the most suitable option among the included DPP-4i for T2DM patients with hyperlipidemia. Tene demonstrated significant efficacy in glycemic control, and can be a first-line choice among the included DPP-4i."

Clinical • Journal • Retrospective data • Review • Diabetes • Dyslipidemia • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus

Sita- and saxagliptin use and autoantibodies to autoimmune bullous diseases: A cross-sectional study. (PubMed, J Eur Acad Dermatol Venereol) - No abstract available

Journal • Observational data • Immunology

SMPDL3B a novel biomarker and therapeutic target in myalgic encephalomyelitis. (PubMed, J Transl Med) - "SMPDL3B emerges as a key biomarker for ME severity and immune dysregulation, with its activity influenced by hormonal and PI-PLC regulation. The ability of vildagliptin and saxagliptin to preserve membrane-bound SMPDL3B and reduce its soluble form via PI-PLC inhibition suggests a novel therapeutic strategy. These findings warrant clinical trials to evaluate their potential in mitigating immune dysfunction and symptom burden in ME."

Biomarker • Journal • CNS Disorders • Fatigue • Metabolic Disorders • PLCB4

The Association of SGLT2i vs DPP4i on Fracture: A Cohort Study in Veterans with Diabetes. (PubMed, Am J Med Open) - "The unweighted sample included 115,124 SGLT2i episodes (104,086 Veterans; 94% empagliflozin; 4% canagliflozin; 2% dapagliflozin) and 213,095 DPP4i episodes (173,724 Veterans; 45% saxagliptin; 15% sitagliptin; 34% alogliptin; 6% Linagliptin). The adjusted hazard ratio (adjusted hazard ratio 0.93 [0.87, 0.99]) excluded increased risk of fractures (adjusted hazard ratio > 1) in SGLT2i users. SGLT2i use as add-on treatment for diabetes was not associated with increased fracture outcomes compared to DPP4i."

Journal • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics

Development of a novel 68Ga-labeled azabicyclohexane-based fibroblast activation protein-targeted tracer (SNMMI 2025) - "Saxagliptin, one of the approved DPPIV inhibitors, has a 2-azabicyclo[3.1.0]hexane-3-carbonitrile motif to mimic Pro... Ga-JC02076 was obtained in 73% yield with >99% chemical purity. The calculated IC50 value of Ga-JC02076 was 29.7±3.5 nM, which was higher than that of Ga-FAPI-04 (1.0±0.4 nM). [68Ga]Ga-JC02076 was obtained within 30 min including radiolabeling and HPLC purification in > 40% decay-corrected radiochemical yield."

Oncology • Solid Tumor • FAP

Development of a novel 68Ga-labeled azabicyclohexane-based fibroblast activation protein-targeted tracer (SNMMI 2025) - "Saxagliptin, one of the approved DPPIV inhibitors, has a 2-azabicyclo[3.1.0]hexane-3-carbonitrile motif to mimic Pro... Ga-JC02076 was obtained in 73% yield with >99% chemical purity. The calculated IC50 value of Ga-JC02076 was 29.7±3.5 nM, which was higher than that of Ga-FAPI-04 (1.0±0.4 nM). [68Ga]Ga-JC02076 was obtained within 30 min including radiolabeling and HPLC purification in > 40% decay-corrected radiochemical yield."

Oncology • Solid Tumor • FAP

Cardiovascular Events in Patients Treated with Sulfonylureas—A Target Trial Emulation (ADA 2025) - "We compared patients initiating individual sulfonylureas (glimepiride, glipizide and glyburide) to patients initiating DPP4i (which were shown in multiple controlled trials to have CV risk similar to placebo). Patients with T2D treated with glipizide as a second agent after metformin had the highest incidence of MACE-4 events compared with patients treated with DPP4i among those initiating a sulfonylurea. Glipizide may not be the optimal agent in treatment of patients with T2D at elevated CV risk."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Beta-Cell Preservation with Early Oral Antidiabetic Medications in Prediabetes (PreDM) (ADA 2025) - "At baseline, subjects received an OGTT and two-step hyperglycemic clamp (+125 and 400 mg/dl) followed by exenatide infusion to quantitate insulin sensitivity (Matsuda Index), insulin secretion (ΔI/ΔG), and beta cell function (disposition index). Subjects then were randomized to receive 24 months of treatment with: (i) Dapagliflozin (DAPA), (ii) Metformin (MET), (iii) Pioglitazone (PIO), or (iv) Saxagliptin (SAXA)... Early pharmacological treatment can prevent progression of PreDM to T2D. DAP and MET improved insulin sensitivity with net weight loss. Despite weight gain, PIO improved total body and adipose insulin sensitivity and robustly increased beta cell function."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Real-World Harm Reduction of Metformin Plus DPP4 Inhibitors versus Metformin Plus Sulfonylureas in Older Adults: A Target Trial Emulation Using German Claims Data. (PubMed, Drugs Aging) - "Deprescribing sulfonylureas and using DPP4i instead may slightly reduce harm in some subgroups of older adults, which supports recommendations of existing lists of potentially inappropriate medications."

Journal • Real-world evidence • Cardiovascular • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Renal Disease • Severe Hypoglycemia • Type 2 Diabetes Mellitus

GLP1 RECEPTOR AGONISTS AND HEPATIC DECOMPENSATION IN PATIENTS WITH MASH CIRRHOSIS: A PROPENSITY-MATCHED ANALYSIS OF THE US COLLABORATIVE NETWORK (DDW 2025) - "We constructed 1-1 propensity-score (PS)-matched cohorts of patients initiating GLP-1RAs (semaglutide, liraglutide, exenatide, dulaglutide, albiglutide, tirzepatide, or lixisenatide) or DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin or sitagliptin). In patients with compensated MASH cirrhosis, GLP-1RAs were associated with significantly lower rates of hepatic decompensation and all-cause mortality compared to DPP-4 inhibitors. These findings suggest a potential therapeutic benefit of GLP-1RAs in this population, warranting further validation through prospective studies."

Clinical • CNS Disorders • Diabetes • Fibrosis • Genetic Disorders • Hematological Disorders • Hepatic Encephalopathy • Hepatocellular Cancer • Hepatology • Immunology • Liver Failure • Metabolic Dysfunction-Associated Steatohepatitis • Nephrology • Obesity • Oncology • Renal Disease • Solid Tumor

Metabolism-associated protein network constructing and host-directed anti-influenza drug repurposing. (PubMed, Brief Bioinform) - "Lisinopril, saxagliptin, and gliclazide were further validated for anti-IVA efficacy in vitro through assays measuring the inhibition of cytopathic effects and viral titers in A549 cells infected with IVA PR8. This workflow paves the way for the rapid repurposing of host-directed antivirals."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Association of long-term use of dipeptidyl peptidase-4 inhibitors with the risk of diabetic retinopathy in patients with diabetes mellitus: a real-world evidence study. (PubMed, Front Pharmacol) - "Of the different DPP-4is, linagliptin at ≤90 or 181-300 was associated with the highest risk of DR. Significant differences were discovered at ≤90, 91-181, and 181-300 cDDD in the risk of DR between patients using Saxagliptin versus sitagliptin. Vildagliptin at ≤90 or 91-180 cDDD was associated with an increased risk of DR, but not at 181-300 cDDD...Sitagliptin at cDDD 181-300 was associated with the greatest DR risk. The potential for DPP-4i to accelerate DR progression should be considered."

HEOR • Journal • Real-world evidence • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Retinal Disorders

Neuroprotective effects of Saxagliptin in traumatic brain injury: ameliorating oxidative stress, neuroinflammation, and apoptosis. (PubMed, Metab Brain Dis) - "Saxagliptin exhibits notable neuroprotective effects in TBI by mitigating oxidative stress, reducing neuroinflammation, and preventing neuronal apoptosis. These findings suggest that Saxagliptin could be a viable therapeutic agent for improving outcomes in TBI management."

IO biomarker • Journal • CNS Disorders • Diabetes • Inflammation • Metabolic Disorders • Vascular Neurology • BCL2 • CASP3 • IL6 • TNFA

Methods for kinetic evaluation of reversible covalent inhibitors from time-dependent IC50 data. (PubMed, RSC Med Chem) - "The application of these new methods is demonstrated by the evaluation of a known inhibitor, saxagliptin, providing results consistent with those obtained by other known methods. This work introduces two new practical methods of evaluation for time-dependent reversible covalent inhibitors, allowing for rigorous characterization to enable the fine-tuning of their binding and reactivity."

Journal